|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang X, Tang H and Chen T: Epidemiology
of gynecologic cancers in China. J Gynecol Oncol. 29:e72018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistic, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mondal D and Sharma DN: External beam
radiation techniques for breast cancer in the new millennium: New
challenging perspectives. J Egypt Natl Canc Inst. 28:211–218. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu LY, Tang J, Zhang CM, Zeng WJ, Yan H,
Li MP and Chen XP: New immunotherapy strategies in breast cancer.
Int J Environ Res Public Health. 14:E682017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bernal-Estévez D, Sanchez R, Tejada RE and
Parra-López C: Chemotherapy and radiation therapy elicits tumor
specific T cell responses in a breast cancer patient. BMC Cancer.
16:5912016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakai K, Hung MC and Yamaguchi H: A
perspective on anti-EGFR therapies targeting triple-negative breast
cancer. Am J Cancer Res. 6:1609–1623. 2016.PubMed/NCBI
|
|
8
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Migali C, Milano M, Trapani D,
Criscitiello C, Esposito A, Locatelli M, Minchella I and Curigliano
G: Strategies to modulate the immune system in breast cancer:
Checkpoint inhibitors and beyond. Ther Adv Med Oncol. 8:360–374.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rapoport AP, Stadtmauer EA, Binder-Scholl
GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B,
Finklestein J, et al: NY-ESO-1-specific TCR-engineered T cells
mediate sustained antigen-specific antitumor effects in myeloma.
Nat Med. 21:914–921. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kunert A, Straetemans T, Govers C, Lamers
C, Mathijssen R, Sleijfer S and Debets R: TCR-Engineered T cells
meet new challenges to treat solid tumors: Choice of antigen, t
cell fitness and sensitization of tumor milieu. Front Immunol.
4:3632013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chinnasamy N, Wargo JA, Yu Z, Rao M,
Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump
DS, et al: A TCR targeting the HLA-A*0201-restricted epitope of
MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen
superfamily in several types of cancer. J Immunol. 186:685–696.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chodon T, Comin-Anduix B, Chmielowski B,
Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A,
et al: Adoptive transfer of MART-1 T cell receptor transgenic
lymphocytes and dendritic cell vaccination in patients with
metastatic melanoma. Clin Cancer Res. 20:2457–2465. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koslowski M, Tureci O, Biesterfeld S,
Seitz G, Huber C and Sahin U: Selective activation of
trophoblast-specific PLAC1 in breast cancer by
CCAAT/enhancer-binding protein beta (C/EBPbeta) isoform 2. J Biol
Chem. 284:28607–28615. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Old LJ: Cancer is a somatic cell
pregnancy. Cancer Immun. 7:192007.PubMed/NCBI
|
|
16
|
Koslowski M, Sahin U, Mitnacht-Kraus R,
Seitz G, Huber C and Tureci O: A placenta-specific gene ectopically
activated in many human cancers is essentially involved in
malignant cell processes. Cancer Res. 67:9528–9534. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leisegang M, Engels B, Meyerhuber P,
Kieback E, Sommermeyer D, Xue SA, Reuss S, Stauss H and Uckert W:
Enhanced functionality of T cell receptor-redirected T cells is
defined by the transgene cassette. J Mol Med (Berl). 86:573–583.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sommermeyer D, Conrad H, Krönig H, Gelfort
H, Bernhard H and Uckert W: NY-ESO-1 antigen-reactive T cell
receptors exhibit diverse therapeutic capability. Int J Cancer.
132:1360–1367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosati SF, Parkhurst MR, Hong Y, Zheng Z,
Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, et al: A
Novel murine T cell receptor targeting NY-ESO-1. J Immunother.
37:135–146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee SY and Sin JI: MC32 tumor cells
acquire Ag-specific CTL resistance through the loss of CEA in a
colon cancer model. Hum Vaccin Immunother. 11:2012–2020. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Q, Liu G, Shao D, Wang J, Yuan H, Chen
T, Zhai R, Ni W and Tai G: Mucin1 mediates autocrine transforming
growth factor beta signaling through activating the c-Jun
N-terminal kinase/activator protein 1 pathway in human
hepatocellular carcinoma cells. Int J Biochem Cell Biol.
59:116–125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang F, Li Q, Ni W, Fang F, Sun X, Xie F,
Wang J, Wang F, Gao S and Tai G: Expression of human full-length
MUC1 inhibits the proliferation and migration of a B16 mouse
melanoma cell line. Oncol Rep. 30:260–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Wang F, Liu G, Yuan H, Chen T, Wang
J, Xie F, Zhai R, Wang F, Guo Y, et al: Impact of Mucin1 knockdown
on the phenotypic characteristics of the human hepatocellular
carcinoma cell line SMMC-7721. Oncol Rep. 31:2811–2819. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yun BL, Cho N, Li M, Jang MH, Park SY,
Kang HC, Kim B, Song IC and Moon WK: Intratumoral heterogeneity of
breast cancer xenograft models: Texture analysis of
diffusion-weighted MR imaging. Korean J Radiol. 15:591–604. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ladygina N, Gottipati S, Ngo K, Castro G,
Ma JY, Banie H, Rao TS and Fung-Leung WP: PI3Kγ kinase activity is
required for optimal T cell activation and differentiation. Eur J
Immunol. 43:3183–3196. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huse M: The T cell-receptor signaling
network. J Cell Sci. 122:1269–1273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Prinz PU, Mendler AN, Masouris I, Durner
L, Oberneder R and Noessner E: High DGK-α and disabled MAPK
pathways cause dysfunction of human tumor-infiltrating CD8+ T cells
that is reversible by pharmacologic intervention. J Immunol.
188:5990–6000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Robertson LK, Mireau LR and Ostergaard HL:
A role for phosphatidylinositol 3-kinase in TCR-stimulated ERK
activation leading to paxillin phosphorylation and CTL
degranulation. J Immunol. 175:8138–8145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Radoja S, Frey AB and Vukmanovic S: T cell
receptor signaling events triggering granule exocytosis. Crit Rev
Immunol. 26:265–290. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Adamina M: When gene therapy meets
adoptive cell therapy: Better days ahead for cancer immunotherapy?
Expert Rev Vaccines. 9:359–363. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stevenson BJ, Iseli C, Panji S, Zahn-Zabal
M, Hide W, Old LJ, Simpson AJ and Jongeneel V: Rapid evolution of
cancer/testis genes on the X chromosome. BMC Genomics. 8:1292007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cocchia M, Huber R, Pantano S, Chen EY, Ma
P, Forabosco A, Ko MS and Schlessinger D: PLAC1, an Xq26 gene with
placenta-specific expression. Genomics. 68:305–312. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gjerstorff MF, Andersen MH and Ditzel HJ:
Oncogenic cancer/testis antigens: Prime candidates for
immunotherapy. Oncotarget. 6:15772–15787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu W, Zhai M, Wu Z, Qi Y, Wu Y, Dai C,
Sun M, Li L and Gao Y: Identification of a novel HLA-A2-restricted
cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in
breast cancer. Amino Acids. 42:2257–2265. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De FP, Luke GA, Hughes LE, Gani D, Halpin
C and Ryan MD: E unum pluribus: Multiple proteins from a
self-processing polyprotein. Trends Biotechnol. 24:68–75. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang X, Liu X, Tao G, Qin M, Yin G, Suo J
and Suo X: ‘Self cleaving’ 2A peptide from porcine teschovirus 1
mediates cleavage of dual fluorescent proteins in transgenic
Eimeria tenella. Vet Res. 47:682016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mizote Y, Uenaka A, Isobe M, Wada H,
Kakimi K, Saika T, Kita S, Koide Y, Oka M and Nakayama E:
Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo
detection of CD4 T cell responses in vaccinated cancer patients.
Vaccine. 32:957–964. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Malyguine AM, Strobl S, Dunham K, Shurin
MR and Sayers TJ: ELISPOT assay for monitoring cytotoxic T
lymphocytes (CTL) activity in cancer vaccine clinical trials.
Cells. 1:111–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Colagiovanni A, Di Renzo L, Sarlo F,
Schiavino D and De Lorenzo A: Role of TNF-alpha polymorphism in
patients with nickel allergy: A marker of susceptibility to contact
polysensitization. Eur Rev Med Pharmacol Sci. 20:2663–2666.
2016.PubMed/NCBI
|
|
40
|
Wang S, Campos J, Gallotta M, Gong M,
Crain C, Naik E, Coffman RL and Guiducci C: Intratumoral injection
of a CpG oligonucleotide reverts resistance to PD-1 blockade by
expanding multifunctional CD8+ T cells. Proc Natl Acad Sci USA.
113:pp. E7240–e7249. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gammaitoni L, Giraudo L, Leuci V,
Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe
MG, Gallo S, et al: Effective activity of cytokine-induced killer
cells against autologous metastatic melanoma including cells with
stemness features. Clin Cancer Res. 19:4347–4358. 2013. View Article : Google Scholar : PubMed/NCBI
|
